The author received editorial/writing support in the preparation of this manuscript, funded by sanofi-aventis, NJ, USA, manufacturer of the LMWH enoxaparin. The author, however, was fully responsible for content and editorial decisions for this manuscript.
Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis†
Article first published online: 29 JAN 2007
Copyright © 2007 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 95, Issue 2, pages 167–174, 1 February 2007
How to Cite
Bergqvist, D. (2007), Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis. J. Surg. Oncol., 95: 167–174. doi: 10.1002/jso.20625
- Issue published online: 29 JAN 2007
- Article first published online: 29 JAN 2007
- Manuscript Accepted: 14 JUN 2006
- Manuscript Received: 15 NOV 2005
Patients with cancer have an increased risk of developing venous thromboembolism (VTE) due to a hypercoagulable state associated with malignancy. This risk is further complicated in patients undergoing cancer-related surgery due to immobility, other cancer treatments, and biologic changes associated with surgery. Despite this relatively high risk of VTE, many patients are not prescribed adequate prophylaxis in the pre- or post-operative periods. This article reviews available measures for thromboprophylaxis in light of current guidelines. J. Surg. Oncol. 2007;95:167–174. © 2007 Wiley-Liss, Inc.